Study of the Innate Immune Response to the Acute Phase of Human Leptospirosis - IMMUNOLEPTO (NCT05413720) | Clinical Trial Compass
CompletedNot Applicable
Study of the Innate Immune Response to the Acute Phase of Human Leptospirosis - IMMUNOLEPTO
Reunion100 participantsStarted 2021-01-06
Plain-language summary
The research hypothesis is based on a suspected strong involvement of the immune system in the genesis of serious manifestations of the disease (hepatitis, renal failure, thrombocytopenia, intra-alveolar hemorrhage). The question asked is that of the state of the immune system (quantitative and qualitative: activation markers, production of cytokines) evaluated by the study of circulating innate immune cells (monocytes, neutrophils, dendritic cells, lymphocytes, platelets).
Who can participate
Age range4 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Age ≥ 4 years;
* Weight ≥ 11 kg;
* with ongoing symptoms compatible with a clinical diagnosis of leptospirosis.
* AND having a diagnosis of leptospirosis confirmed according to standard care procedures: preferably by Polymerase Chain Reaction (PCR) (blood or urine) or, failing that, serology indicating a recent infection (positive Immunoglobulin M (IgM) or Microscopic Agglutination Test (MAT) technique with titer \>1/400 for a pathogenic serogroup)
* AND affiliated to a Social Security scheme
Exclusion Criteria:
* Refusal of participation by the patient or his entourage if the patient is physically unable to give his opinion (coma, resuscitation, etc.).
* Not affiliated with social security
* Immunosuppression that may interfere with the interpretation of the results: chemotherapy in progress, immunosuppressants in progress for organ transplantation or autoimmune disease
* Patient under legal protection (Guardianship, Curators)
What they're measuring
1
proportion of activated monocyte cells (CD14+CD16+ phenotype) within monocytes